text:
LOS ANGELES — Jaws — from Nuggets owner Stan Kroenke behind the Denver bench, to the fans under the NBA title banners — dropped.
Did that just happen? Andre Miller drove to the basket, but Dwight Howard volleyball-blocked the shot to the right corner. And the thing landed right in the happy hands of Denver's Danilo Gallinari, who swished the corner 3.
The shot gave Denver a 108-102 lead with 13.8 seconds left. Kobe Bryant, being Kobe Bryant, hit a 3, but Miller calmly hit two free throws and the Nuggets escaped the Staples Center with a 112-105 victory over the Lakers on Sunday.
"You don't have a lot of time to think," Gallinari said, "especially in those situations. I was just ready to shoot it. ... It was a lucky bounce off of Dwight, Metta World Peace was right there, ready to block the shot, so I had to release it quick. I'm glad. It was very important we won that game."
Lawson was Lawsome. When Denver guard Ty Lawson sank a 3-pointer with 6:12 left, it gave the visitors a 99-89 lead. It was one of the game's most impressive shots, on one of Ty's most impressive nights. He had 10 assists after only three quarters. He also made a fearless layup with 1:18 left, finishing with 21 points and those 10 assists and no turnovers.
"Layups break teams' hearts, and when you have two guys with 20 assists and one turnover, you have a heck of chance to win the game," Denver coach George Karl said of Lawson and Miller, who had 12 points and 10 assists.
When the season began, it was so easy to believe. Would the Lakers ever lose? On paper, it was maybe the best starting lineup of all time. Kobe. Dwight. Nash. Pau.
Well, the Lakers are falling apart, like an old building slowly cracking and decaying. The Lakers suffered their latest blow Sunday, courtesy of the Nuggets.
JaVale McGee, "The Big Unpredictable," had one of his better games, playing consistently and effectively.
He floated a sky hook over Pau Gasol. He stole the ball once from Howard. He defended with ferocity. And he created a huge turnover, leading to a Miller basket.
He had 17 points and six rebounds, and even his plus-minus stood out: plus-14.
In the previous two games combined, McGee was 3-of-12 shooting for nine points and nine rebounds in 35 minutes.
"He was very good playing our concepts on defense, especially on the help side," Gallinari said of McGee. "And he went (strong) against two of the three best big men in our league, responding well."
Bryant, the league's leading scorer, started the game 4-for-13 from the field but finished 11-for-26 for a game-high 29 points.
This matchup was the third between the teams, which have faced each other in the postseason in three of the past five years.
Los Angeles routed Denver in the first matchup, at the Staples Center on Nov. 30, 122-103.
But the Nuggets got revenge the day after Christmas when they beat the Lakers 126-114 at the Pepsi Center. The lasting image of that matchup was a helpless Howard thrusting his hands to the face of Denver forward Kenneth Faried on a soaring shot attempt in the paint. Howard was ejected, and later fined by the NBA, for the flagrant foul.
Well, Howard fared a little better this go-around against Denver — 14 points and 26, yes 26, rebounds.
Nuggets Recap
What you might have missed. With 1:05 left, and Denver up 105-97, Pau Gasol was fouled by JaVale McGee, but Gasol's nose was bloodied. Because Gasol couldn't return, Denver coach George Karl got to choose which Lakers player would shoot the free throws, so Karl chose seldom-used Earl Clark. Alas, Clark made both. ... In the second quarter, Andre Iguodala made a splendid move, twirling the ball around his pelvis, 360 degrees, while darting past an opponent and making a layup.
Final thought. Great poise in tough place to play.
Up next. Vs. Orlando, Wednesday, 7 p.m.


text:
Young Jewish Torontonians made their way in droves to the picturesque Distillery District earlier this month for the first-ever kosher wine-tasting festival put on by the Jewish Urban Meeting Place (JUMP).
The fundraiser for the nonprofit, which provides programming for young Jewish professionals, featured more than a dozen kosher wines from around the world.
"We wanted to do something different, that hadn't been done before," said Lexi Mitz, one of the event's co-chairs, along with Adir Koschitzky, Yonah Krakowsky, Debbie Osiel and Isaac Apter.
Mitz said the evening of wine tasting, live jazz music and hors d'oeuvres, held at the trendy Arta Gallery, was designed to let people have fun in a chic setting while learning about what the kosher wine world has to offer and "what kosher life is all about."
She added that many people don't know about the great variety and quality of kosher wines.
Although kosher wine tastings often feature exclusively Israeli wines, JUMP offered guests a wider variety of reds and whites to choose from.
Alana Kayfetz, JUMP's director of strategic development, modelled the festival on one held in Jerusalem that features kosher wines from around the world.
"We said, 'Wait a minute, we could totally make this happen [here],'" Kayfetz said of planning the event with her team of volunteers.
The evening raised money for JUMP, and guests had the opportunity to enter a raffle to win a free trip to Israel.
"This is a combination of people who are interested in supporting JUMP and who are interested in wine from around the world," said Mitz of the crowd of about 250 people who attended the event.
After an evening of wine tasting themselves, the organizers selected wines from a dozen kosher wineries from Italy, Australia, Israel, Canada and the United States. The JUMP Wine Festival featured everything from dry red and white wines to sparkling wine and even blueberry wine.
The wines were set up at pouring stations around the gallery. For guests who were new to wine tasting, cards were available with information about what to look for in a wine, explaining the importance of things such as aroma, colour, acidity and sweetness.
JUMP also brought in professional wine experts who were able to advise tasters about the different bottles.
Mitz said that this "one-on-one" experience with the wine experts helped people learn useful information about the wines they were drinking.
The packed gallery of wine tasters enjoyed the music, food and drinks late into the night, and although much of downtown Toronto experienced power outages that evening, the lights at the Arta Gallery stayed on all night.

subset: commoncrawl


text:
Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study
This study has been completed.
H. Lee Moffitt Cancer Center and Research Institute
Provectus Pharmaceuticals
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
First received: December 21, 2012
Last updated: April 18, 2017
Last verified: April 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The main purpose of this study is to find out more about how PV-10 works in melanoma tumors. Researchers also want to find out if there are changes in the body's immune cells (cells that fight infection and illnesses) after PV-10 is given, both inside the melanoma tumors and circulating in the blood.
|Drug: PV-10 Procedure: Surgery
|Phase 1
|Study Type:
|Study Design:
|Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:
|Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study
Resource links provided by NLM:
MedlinePlus related topics: Melanoma
Drug Information available for: Rose bengalU.S. FDA Resources
Further study details as provided by H. Lee Moffitt Cancer Center and Research Institute:
Primary Outcome Measures:
- Occurrence of Change in Infiltration of Immune Cells [ Time Frame: At baseline and 7-14 days after PV-10 treatment ]The pre-treatment blood sample and tumor biopsies will be the control for the post-PV-10 blood samples and resected tumor samples. Tumor core needle biopsies will be collected from the designated injected and uninjected lesions one week prior to intralesional PV-10 therapy. Biopsy samples will be fixed in formalin and embedded in paraffin for immunohistochemical (IHC) staining. On day 0, the injected lesion will be treated with up to 5 mL of PV-10. Seven to 14 days after intralesional PV-10 treatment, the injected and uninjected lesions will be resected. A portion of each tumor equivalent to a core needle biopsy specimen will be fixed in formalin and embedded in paraffin for IHC staining. Immune cell infiltration will be compared between untreated baseline lesions and post-treatment lesions (injected or uninjected) by a blinded pathologist at Moffitt Cancer Center. Measurement is the ordinal level of the T-cell infiltration into tumors with three levels: 0, no brisk, and brisk.
Secondary Outcome Measures:
- Frequency and Phenotype of Circulating Immune Cells in Peripheral Blood Mononuclear Cells (PBMC) [ Time Frame: At baseline, 7-14 days after treatment and 21-28 days after treatment ]This secondary endpoint is to enumerate and phenotype patient immune cells in peripheral blood before and after intralesional (IL) PV-10 treatment. The pre-treatment blood sample and tumor biopsies will be the control for the post-PV-10 blood samples and resected tumor samples. T cells will be enumerated and phenotyped in patient blood one week prior to and 7-14 days after intralesional PV-10 therapy. An additional blood draw 14 days post surgery will take place at the end of the study at the time of the surgical follow-up/end of study visit. These samples will be used for in vitro experiments in order to determine the frequency and phenotype of T cells in the blood by flow cytometry.
- Titer of Anti-tumor IgG in the Serum [ Time Frame: At baseline, 7-14 days after treatment and 21-28 days after treatment ]This secondary endpoint is to enumerate anti-tumor immunoglobulin G (IgG) in peripheral blood before and after IL PV-10 treatment. Titer of anti-tumor IgG in the serum prior to, 7-14 days after, and 21-28 days after PV-10 treatment. The pre-treatment blood sample and tumor biopsies will be the control for the post-PV-10 blood samples and resected tumor samples. Serum will be phenotyped from patients one week prior to, 7-14 days after and 21-28 days after IL PV-10 therapy. Serum will be isolated from peripheral blood by centrifugation and will be used to stain patient tumor samples obtained from surgical resection. Bound serum antibodies will be detected by staining with antihuman IgG antibodies and detected by flow cytometry.
- Occurrence of Adverse Events (AEs) [ Time Frame: During PV-10 administration visit, after 7-14 days, at study end (day 28 or early termination) ]Local and systemic toxicity signs and symptoms per the Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Any adverse experiences associated with participation on the trial will be recorded. Adverse events will be assessed within 30 minutes following PV-10 administration and 4 hours after PV-10 administration. Adverse events assessment: Questions about how participants have been feeling and any changes in the way participants feel immediately after the study drug was given and 4 hours later.
|Study Start Date:
|January 24, 2013
|Study Completion Date:
|April 2017
|Primary Completion Date:
|December 29, 2015 (Final data collection date for primary outcome measure)
|Assigned Interventions
Experimental: Immunotherapy Followed by Surgery
PV-10 administration, adverse events assessment, surgery to remove melanoma tumors, follow-up visit.
Drug: PV-10
PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
Other Name: 10% rose bengal disodiumProcedure: Surgery
Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
|Ages Eligible for Study:
|18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
- Patients who are diagnosed with metastatic melanoma, or who are suspected to have metastatic melanoma and are subsequently proven to have metastatic melanoma by biopsy
- Patients who are planned to undergo surgical resection of at least two foci of palpable cutaneous or subcutaneous metastatic melanoma, for either palliative or therapeutic intent and who consent for preoperative core biopsies of at least two of the resectable lesions prior to surgery
- Patients who have given informed consent to participate in the study
Exclusion Criteria:
- Patients who decline consent for this study
- Patients who have previously received PV-10 therapy
- Patients who were suspected to have metastatic melanoma but are not proven by preoperative biopsy will be replaced and not counted against the accrual goal
- Patients who do not undergo surgical resection of at least two metastatic melanoma lesions including the PV-10 treated lesion will be replaced and not counted against the accrual goal.
- Patients whose melanoma lesions are contiguous with, encompass or infiltrate a major blood vessel
- Patients with an allergy to shellfish due to reported cross-reactivity to PV-10
- Patients with previous sensitivity to iodide
- Patients who do not have a treatable target lesion on a portion of the body other than the head or neck
Concurrent or Intercurrent Illness:
- Patients with a condition of impaired wound healing (such as uncontrolled diabetes mellitus or immunosuppressive steroid dependence) such that in the opinion of the PI it is unsafe for the patient to undergo intralesional PV-10 treatment
- Patients with severe peripheral vascular disease (i.e., claudication occurring after less than 200 meters of walking, rest pain, ischemic ulceration or gangrene)
- Patients with significant concurrent or intercurrent illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the principal investigator (PI), compromise their safety or compliance or interfere with interpretation of study results
- Patients with uncontrolled thyroid disease, goiter, partial thyroidectomy, previous radioiodine or surgically-treated Graves' hyperthyroidism or cystic fibrosis
- Patients with clinically significant cardiovascular, cerebrovascular, peripheral vascular, renal, gastrointestinal, pulmonary, immunological, endocrine, bone marrow or central nervous system disorders that have required hospitalization within the past 12 months
- Female patients who have a positive pregnancy test or are lactating.
- Fertile patients who do not agree to use effective contraception (i.e., oral contraceptives, intrauterine devices, double barrier methods such as condoms and diaphragms, abstinence or equivalent measures) beginning at the time of signing consent until after surgery.
- Patients who are dependent upon concomitant medications that predispose to photosensitivity who cannot stop the medication(s) from the period starting 24 hours prior to and ending 24 hours after PV-10 treatment will be excluded.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01760499
Please refer to this study by its ClinicalTrials.gov identifier: NCT01760499
|United States, Florida
|H. Lee Moffitt Cancer Center and Research Institute
|Tampa, Florida, United States, 33612
Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Provectus Pharmaceuticals
|Principal Investigator:
|Amod A. Sarnaik, M.D.
|H. Lee Moffitt Cancer Center and Research Institute
More Information
Additional Information:
Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 20, 2017
Additional Information:
|Responsible Party:
|H. Lee Moffitt Cancer Center and Research Institute
|ClinicalTrials.gov Identifier:
|NCT01760499 History of Changes
|Other Study ID Numbers:
|Study First Received:
|December 21, 2012
|Last Updated:
|April 18, 2017
Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:
Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
ClinicalTrials.gov processed this record on September 20, 2017


text:
A NEW media area will allow theatre-goers the chance to get social.
The Courtyard in Hereford has created the public area complete with five Apple iMacs in part of the main foyer as part of the Arts Council England and Herefordshire Council capital improvement programme.
Users at the Edgar Street arts venue's film-making workshops for youg people will be able to use the facility to edit films and images.
Ian Archer, chief executive of the Courtyard, said: "We are delighted that the generous support of our partners has enabled us to create a digital media suite for our visitors.
"Access to digital media facilities and the opportunities this can open up is so important. This great new facility provides free access to the digital world for members of the local community and the wider public."
The iMacs can be used to browse the internet, prepare presentations and undertake other tasks in an internet café style.
The new service is free to access, although a returnable £5 security deposit is required, and it is open Monday to Sunday.
For more information, go to courtyard.org.uk or call 01432 340555.


text:
'"He works hard at staying sharp," coach Lindy Ruff said. "He's going to be in one of these two games, and he's done his best to stay ready. We're giving him the extra work. He's gone out before practice and gone through stuff with [goalie coach] Jimmy [Corsi], so we know he's going to be there for us."'
You are here: Home / SabresBeat / Lalime gets sharp as next start nears


text:
French F4 Champion and winner in the Eurocup Formula Renault 2.0, Matthieu Vaxivière has moved up to the next level. The driver from Limoges is now competing in the Formula Renault 3.5 Series in the prestigious Lotus team. Right from the start of the pre-season tests he put his black and gold car among the front-runners.
"I learned to get to know the team, the engineers and my team-mate. The latter has a completely different driving style to mine, which is very useful to help me improve," said Matthieu. "Although the programme was pretty intense we kept on upping the pace. I acquired useful data especially during the simulations in the last few days."
The Frenchman went all out during the winter break to be ready to take on the challenge of a category that has seen numerous drivers hit the headlines like 4-time F1 World Champion Sebastian Vettel.
"I did a huge amount of work on my physical fitness and that's not going to stop as I'll continue all year. I also improved my driving and my mental state in order to progress. In testing the accent was placed on qualifying as it's the key throughout the season."
Despite being only 19 Vaxivière has already tried his hand in several different categories since his debut in competition. After his experience in Mijet VdeV, GT, the Porsche Carrera Cup and the Andros Trophy for Electric Cars, he is now tackling the prestigious World Endurance Championship.
"My aim is Formula 1 but it's important to be able to create openings for yourself. From this point of view it's great to be making my debut in the WEC. Testing went off well and I'm ready to tackle the season in a relaxed frame of mind.
"In the World Series by Renault my aim is to be the best rookie and finish in the top five in the championship. In the WEC we'll have to keep a close eye on the evolution of the Balance of Performance, which can have a big impact on our competitiveness, but I'm confident. One thing's sure I can't wait to start racing."
Vaxivière's season kicks off this weekend with the first round of the Formula Renault 3.5 Series at Monza. The following weekend he will race in the opening round of the World Endurance Championship at Silverstone, and then he'll be back in single-seaters at Motorland Aragon at the end of the month.


text:
ATLANTA and BRUSSELS, Nov. 9, 2012 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology treatment and research, is proud to announce new data on two compounds in its immunology portfolio for a broad range of rheumatic conditions at the American College of Rheumatology's (ACR) 2012 Annual Scientific Meeting in Washington, D.C., November 10-14. The data include posters and oral presentations on Cimzia® (certolizumab pegol) for the treatment of moderate to severe rheumatoid arthritis in adults, as well as posters and oral presentations on investigational data on certolizumab pegol for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and axSpA without radiographic evidence of AS (non-radiographic axSpA [nr-axSpA]). Data will also be presented on epratuzumab, which is being evaluated for the treatment of systemic lupus erythematosus (SLE).
"At UCB, we remain steadfastly committed to rheumatology and to providing treatments for patients with severe chronic conditions. The multiple data sets we are presenting at this year's ACR meeting highlight our ongoing scientific research in immunology aimed at helping to address the needs of patients living with a broad range of rheumatic diseases," said Carol Satler, MD, Vice President, U.S. Medical Affairs, UCB, Inc. "We are looking forward to the presentation of data investigating the long-term use of Cimzia® in adult patients with moderate to severe RA, as well as Cimzia® data on household productivity. Additionally, we are pleased to announce first results in Phase III data for psoriatic arthritis and axial spondyloarthritis."
In the U.S., Cimzia® is indicated for the treatment of adult patients with moderately-to-severely active RA. In the European Union, Cimzia® in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients inadequately responsive to disease-modifying anti-rheumatic drugs (DMARDs) including MTX. Cimzia® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate.
Patients treated with Cimzia® are at an increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Cimzia® should be discontinued if a patient develops a serious infection or sepsis. Additional important safety information is included at the end of this press release.
Following is a guide to UCB-sponsored data presentations being held from Sunday, November 11-Wednesday, November 14, 2012.
Cimzia® for Rheumatoid Arthritis
Investigational Studies of Certolizumab Pegol for Axial Spondyloarthritis (Including Ankylosing Spondylitis and axSpA without radiographic evidence of AS (non-radiographic axSpA [nr-axSpA])
Investigational Studies of Certolizumab Pegol for Psoriatic Arthritis
Investigational Studies of Epratuzumab for Systemic Lupus Erythematosus
About Rheumatoid Arthritis (RA)RA affects more than 1.3 million Americans,and it is estimated that 5 million people suffer from RA globally. Prevalence is not split evenly between genders, since women are three times more likely to be affected than men. Although RA can affect people of all ages, the onset of the disease usually occurs between 40-60 years of age.
About Spondyloarthritis (SpA)SpA is the overall name of a family of inflammatory rheumatic diseases that can affect the spine and joints, ligaments and tendons. There are two main types of clinical presentation of SpA axSpA (symptoms predominantly related to the spine) and peripheral SpA (symptoms predominantly related to the peripheral joints).
About Ankylosing Spondylitis (AS)AS is a chronic inflammatory rheumatic disease of the spine and is the most defined subset of axSpA. The symptoms of AS can vary, but most people experience back pain and stiffness due to inflammation which can proceed to fusion of the vertebrae. The condition can be severe, with around 1 in 10 people at risk of long-term disability. The condition usually occurs between 15 and 35 years of age, and rarely starts in old age, with prevalence estimated to be between 0.1% - 1.1% of the population. AS is more common in men than in women.
About Axial Spondyloarthritis (axSpA) without radiographic evidence of AS Patients with no definitive sacroiliitis on conventional radiographs, but who are showing either sacroiliitis on MRI or are HLA-B27 positive, have axSpA without radiographic evidence of AS (non-radiographic axSpA [nr-axSpA]).
About Psoriatic Arthritis (PsA)PsA is a condition involving joint inflammation that usually occurs in combination with a skin disorder called psoriasis. Signs and symptoms of PsA include stiff, painful joints with warmth and swelling in the joints and surrounding tissues. In the U.S. it is estimated that PsA affects an estimated 24 in 10,000 people. Between 5 and 10 percent of people with psoriasis develop psoriatic arthritis, according to most estimates, with some studies suggesting a figure as high as 30 percent.
About Systemic Lupus Erythematosus (SLE)SLE, commonly referred to as lupus, is a chronic and potentially fatal autoimmune disease with a variable and unpredictable course.Antibodies are generated against the body's own nuclear proteins, causing the immune system to attack its own cells and tissues, resulting in inflammation and tissue damage. This can occur in any part of the body, but most often targets the heart, joints, skin, lungs, blood vessels, liver, kidneys and nervous system.
About Cimzia®Cimzia® is the only PEGylated anti-TNF (Tumor Necrosis Factor). Cimzia® has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. The U.S. Food and Drug Administration (FDA) has approved Cimzia® for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy and for the treatment of adults with moderately to severely active rheumatoid arthritis. Cimzia® in combination with MTX is approved in the EU for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease-modifying antirheumatic drugs (DMARDs) including MTX. Cimzia® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia® is a registered trademark of UCB PHARMA S.A.Please visit www.cimzia.com for full prescribing information for CIMZIA®.
Risk of Serious Infections and MalignancyPatients treated with CIMZIA are at an increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. CIMZIA should be discontinued if a patient develops a serious infection or sepsis. Reported infections include:
The risks and benefits of treatment with CIMZIA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.
Patients treated with CIMZIA are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease.
Treatment with CIMZIA should not be initiated in patients with an active infection, including clinically important localized infections. CIMZIA should be discontinued if a patient develops a serious infection or sepsis. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (e.g. corticosteroids or methotrexate) may be at a greater risk of infection. Patients who develop a new infection during treatment with CIMZIA should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for immunocompromised patients, and appropriate antimicrobial therapy should be initiated. Appropriate empiric antifungal therapy should also be considered while a diagnostic workup is performed for patients who develop a serious systemic illness and reside or travel in regions where mycoses are endemic.
MalignanciesDuring controlled and open-labeled portions of CIMZIA studies of Crohn's disease and other diseases, malignancies (excluding non-melanoma skin cancer) were observed at a rate of 0.5 per 100 patient-years among 4,650 CIMZIA-treated patients versus a rate of 0.6 per 100 patient-years among 1,319 placebo-treated patients. In studies of CIMZIA for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 CIMZIA-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. In CIMZIA RA clinical trials (placebo-controlled and open label) a total of three cases of lymphoma were observed among 2,367 patients. This is approximately 2-fold higher than expected in the general population. Patients with RA, particularly those with highly active disease, are at a higher risk for the development of lymphoma. The potential role of TNF blocker therapy in the development of malignancies is not known.
Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy </=18 years of age), of which CIMZIA is a member. Approximately half of the cases were lymphoma (including Hodgkin's and non-Hodgkin's lymphoma, while the other cases represented a variety of different malignancies and included rare malignancies associated with immunosuppression and malignancies not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.
Cases of acute and chronic leukemia have been reported with TNF-blocker use. Even in the absence of TNF-blocker therapy, patients with RA may be at a higher risk (approximately 2-fold) than the general population for developing leukemia.
Heart FailureCases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. CIMZIA has not been formally studied in patients with CHF. Exercise caution when using CIMZIA in patients who have heart failure and monitor them carefully.
HypersensitivitySymptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following CIMZIA administration. If such reactions occur, discontinue further administration of CIMZIA and institute appropriate therapy.
Hepatitis B ReactivationUse of TNF blockers, including CIMZIA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating CIMZIA therapy. Exercise caution in prescribing CIMZIA for patients identified as carriers of HBV, with careful evaluation and monitoring prior to and during treatment. In patients who develop HBV reactivation, discontinue CIMZIA and initiate effective anti-viral therapy with appropriate supportive treatment.
Neurologic ReactionsUse of TNF blockers, including CIMZIA, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis, and with peripheral demyelinating disease, including Guillain-Barre syndrome. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA. Exercise caution in considering the use of CIMZIA in patients with these disorders.
Hematologic ReactionsRare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) has been infrequently reported with CIMZIA. Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on CIMZIA. Consider discontinuation of CIMZIA therapy in patients with confirmed significant hematologic abnormalities.
Drug InteractionsAn increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination with anakinra or abatacept. Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also result from the use of CIMZIA in these combinations. Therefore, the combination of CIMZIA with anakinra, abatcept, rituximab, or natalizumab is not recommended. Interference with certain coagulation assays has been detected in patients treated with CIMZIA. There is no evidence that CIMZIA therapy has an effect on in vivo coagulation. CIMZIA may cause erroneously elevated aPTT assay results in patients without coagulation abnormalities.
AutoimmunityTreatment with CIMZIA may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. Discontinue treatment if symptoms of lupus-like syndrome develop.
ImmunizationsDo not administer live vaccines or live-attenuated vaccines concurrently with CIMZIA.
Adverse ReactionsIn controlled Crohn's clinical trials, the most common adverse events that occurred in >/=5% of CIMZIA patients (n=620) and more frequently than with placebo (n=614) were upper respiratory infection (20% CIMZIA, 13% placebo), urinary tract infection (7% CIMZIA, 6% placebo), and arthralgia (6% CIMZIA, 4% placebo). The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 8% for CIMZIA and 7% for placebo.
In controlled RA clinical trials, the most common adverse events that occurred in >/= 3% of patients taking CIMZIA 200 mg every other week with concomitant methotrexate (n=640) and more frequently than with placebo with concomitant methotrexate (n=324) were upper respiratory tract infection (6% CIMZIA, 2% placebo), headache (5% CIMZIA, 4% placebo), hypertension (5% CIMZIA, 2% placebo), nasopharyngitis (5% CIMZIA, 1% placebo), back pain (4% CIMZIA, 1% placebo), pyrexia (3% CIMZIA, 2% placebo), pharyngitis (3% CIMZIA, 1% placebo), rash (3% CIMZIA, 1% placebo), acute bronchitis (3% CIMZIA,1% placebo), fatigue (3% CIMZIA, 2% placebo). Hypertensive adverse reactions were observed more frequently in patients receiving CIMZIA than in controls. These adverse reactions occurred more frequently among patients with a baseline history of hypertension and among patients receiving concomitant corticosteroids and non-steroidal anti-inflammatory drugs. Patients receiving CIMZIA 400mg as monotherapy every 4 weeks in RA controlled clinical trials had similar adverse reactions to those patients receiving CIMZIA 200mg every other week. The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 5% for CIMZIA and 2.5% for placebo.
For full prescribing information, please go to:http://www.cimzia.com/pdf/Prescribing_Information.pdf
Cimzia® (certolizumab pegol) in EU/ EEA important safety information
Cimzia® was studied in 2367 patients with RA in controlled and open label trials for up to 57 months. The commonly reported adverse reactions (1-10%) in clinical trials with Cimzia® and post-marketing were viral infections (includes herpes, papillomavirus, influenza), bacterial infections (including abscess), rash, headache (including migraine), asthenia, leukopaenia (including lymphopaenia, neutropaenia), eosinophilic disorder, pain (any sites), pyrexia, sensory abnormalities, hypertension, pruritis (any sites), hepatitis (including hepatic enzyme increase), injection site reactions and nausea. Serious adverse reactions include sepsis, opportunistic infections, tuberculosis, herpes zoster, lymphoma, leukaemia, solid organ tumours, angioneurotic edema, cardiomyopathies (includes heart failure), ischemic coronary artery disorders, pancytopaenia, hypercoagulation (including thrombophlebitis, pulmonary embolism), cerebrovascular accident, vasculitis, hepatitis/hepatopathy (includes cirrhosis), and renal impairment/nephropathy (includes nephritis). In RA controlled clinical trials, 5% of patients discontinued taking Cimzia® due to adverse events vs. 2.5% for placebo.Cimzia® is contraindicated in patients with hypersensitivity to the active substance or any of the excipients, active tuberculosis or other severe infections such as sepsis or opportunistic infections or moderate to severe heart failure.
Serious infections including sepsis, tuberculosis and opportunistic infections have been reported in patients receiving Cimzia®. Some of these events have been fatal. Monitor patients closely for signs and symptoms of infections including tuberculosis before, during and after treatment with Cimzia®. Treatment with Cimzia must not be initiated in patients with a clinically important active infection. If an infection develops, monitor carefully and stop Cimzia® if infection becomes serious. Before initiation of therapy with Cimzia®, all patients must be evaluated for both active and inactive (latent) tuberculosis infection. If active tuberculosis is diagnosed prior to or during treatment, Cimzia® therapy must not be initiated and must be discontinued. If latent tuberculosis is diagnosed, appropriate anti-tuberculosis therapy must be started before initiating treatment with Cimzia®. Patients should be instructed to seek medical advice if signs/symptoms (e.g. persistent cough, wasting/weight loss, low grade fever, listlessness) suggestive of tuberculosis occur during or after therapy with Cimzia®.
Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Cimzia® who are chronic carriers of the virus (i.e. surface antigen positive). Some cases have had a fatal outcome. Patients should be tested for HBV infection before initiating treatment with Cimzia®. Carriers of HBV who require treatment with Cimzia® should be closely monitored and in the case of HBV reactivation Cimzia® should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated. TNF antagonists including Cimzia® may increase the risk of new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease; of formation of autoantibodies and uncommonly of the development of a lupus-like syndrome; of severe hypersensitivity reactions. If a patient develops any of these adverse reactions, Cimzia® should be discontinued and appropriate therapy instituted.
With the current knowledge, a possible risk for the development of lymphomas, leukaemia or other malignancies in patients treated with a TNF antagonist cannot be excluded. Rare cases of neurological disorders, including seizure disorder, neuritis and peripheral neuropathy, have been reported in patients treated with Cimzia®.
Adverse reactions of the hematologic system, including medically significant cytopenia, have been infrequently reported with Cimzia®. Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on Cimzia®. Consider discontinuation of Cimzia® therapy in patients with confirmed significant hematological abnormalities.
The use of Cimzia® in combination with anakinra or abatacept is not recommended due to a potential increased risk of serious infections. As no data are available, Cimzia® should not be administered concurrently with live vaccines. The 14-day half-life of Cimzia® should be taken into consideration if a surgical procedure is planned. A patient who requires surgery while on Cimzia® should be closely monitored for infections.
Please consult the full prescribing information in relation to other side effects, full safety and prescribing information. European SmPC date of revision June 2012.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf
For further Information:Andrea Levin, Associate Director, U.S. Communications and Public Relations, UCB770.970.8352,


text:
149 Enamel Heart **
Vetro No. 19 Gel Pod 149 Enamel Heart. No. 19 Color Gel was developed to meet the colors and textures all nail technicians are seeking for. A color collection of over 250 high quality diversified colors, No. 19 deserves to be called elegance. Three types of texture are available in response to art specifications. 4ml/0.13oz. LED 5 sec; UV 60 sec. Made in Japan.
Medium **
Offered by Official Vetro USA
Product SKU:


text:
It may be Easter and Passover weekend, but you'll still find plenty of things to do this weekend.
If you have additional suggestions, please share them in the comments below:
Tartan Day Festival
All the things you love about Scotland — haggis, bagpipes, kilts — will be celebrated at this festival hosted by local Scottish organizations.
You'll see performances by the House of Scotland Pipe Band and the San Diego School of Highland Dancing, among others. There will also be traditional food like meat pies and mush peas for purchase.
Details: San Diego Tartan Day Festival. 11 a.m. to 4 p.m. Saturday. House of Scotland, International Cottages, Balboa Park. Free. tartandaysd.com
Easter Egg Hunts Galore
Looking for some brightly colored eggs and jelly beans? Here's a list of Easter egg hunts and brunches around the county.
Cinema Under the Stars
Cameron Crowe's sweet "We Bought a Zoo," which is based on a true story, will be screened at the cozy Mission Hills outdoor theater. The film stars Matt Damon and Scarlet Johansson.
The small movie house with the recliners and cozy blankets actually has radiant heat and a weatherproof retractable dome, so you can still enjoy that outside feeling even if it's chilly out.
Details: 8 tonight and Saturday. 4040 Goldfinch St., Mission Hills. $15 (cash or checks only); (619) 295-4221 or topspresents.com.
Spring Harp Fest
For this festival, we're actually talking about harmonicas, not the big fancy harps you see in hotel lobbies.
Some of SoCal's best harmonica players will gather in La Mesa to perform and promote appreciation of the tiny, mouth instrument. This family-friendly event is casual, bringing lawn chairs and your own harmonica is encouraged.
Details: Noon to 6 p.m. Saturday. Harry Griffen Regional Park, 9550 Milden St. La Mesa. Free; springharpfest.org
Strawberry and Flower Fields Forever
This event appreciates the sweet, red strawberry with strawberry-flavored food, strawberry-themed crafts and even a strawberry-shortcake-eating competition. The festivities also include vibrant displays from the MiraCosta College floral design competition, art vendors and more. The event is free with admission to the park, and while you're there, don't forget to roam through the sweet-pea maze.
Details: 9 a.m. to 6 p.m. Saturday. The Flower Fields at Carlsbad Ranch, 5704 Paseo del Norte, Carlsbad. $6 to $11. (760) 431-0352 or theflowerfields.com


text:
Sign up for the Physical Therapy Club's BOMBER BLITZ 5K!!!!
As part of Ithaca College's Family Weekend, the Physical Therapy Club is hosting the 5th Annual Bomber Blitz 5K Walk/Run.
The event will take place on Sunday, November 4th at 11am, with pre-registration held at 10am. The race will start in the Terrace Parking Lot near the Softball Fields. Registration is $10 and all of the money raised will go to the Ithaca Healthcare Alliance, a non-profit organization that provides free healthcare to our community (for more information, see http://www.ithacahealth.org/).
Register before October 10th and receive a FREE t-shirt!!! Light Refreshments will also be provided after the race by Ithaca Bakery! Prizes will be awarded to the overall top female and male runner! Registration will also be accepted the day of the race!
Registration forms are located here:
All registration forms can be mail or dropped off to the PT Office (335 Smiddy Hall). Please make checks payable to Ithaca College or bring exact change when dropping off forms.
Individuals with disabilities requiring accommodations should contact the PT Club at firstname.lastname@example.com. We ask that requests for accommodations be made as soon as possible.
Originally published in Intercom: Sign up for the Physical Therapy Club's BOMBER BLITZ 5K!!!!.


text:
Results 16 to 20 of 148
August 26th, 2013 11:33 AM #16
Willow & Violet are both great. I think Willow goes a bit better with Eve, since she already has a prominent V sound in her name.
Aurora is naturey and princessy and could be a nice A-letter mn to mirror Anastasia. Liberty could make a bold statement in the middle as well.
A lot of your more exotic choices (Sunniva, Ivany/Iverine, Anatolia) seem to fit better as middles in my opinion.
Fidelia- Sounds a bit like a virtue name which your husband seems to like, but is more serious than Felicity; nn Fia
Felicia- a flower name (which it seems you favor); Still sounds somewhat like Felicity for hubby, but is not as frilly; nn Fia
"Queen" themed names- Adelaide, Astrid, Beatriz, Cynthia, Fabiola (Fia?), Gloria/Gloriana, Isabel, Juno, Margaret, Sibel, Victoria
I also love this simple site for looking at flower names... List of Flowers that start with A ...Where you can search by letter to make sure you don't use CZEPT. Husband likes a lot of A names so perhaps there is one you like that isn't "too weird" lol. Good luck! =]Dominic James~ {7}
Benedict : Felicity : Gabriel : Jude : Lavender : Rowena
August 26th, 2013 11:42 AM #18
Edited for privacy.
Last edited by saracita00; January 16th, 2014 at 05:39 PM.
Mama to C, Z, E, P, D, & G
Considerations In Progress for Agent 007
Horatio Frederic Eto :: Horatio Ethan Amadeus
Rainier Ozias Ethan :: Rainier Ozias Eto
girl names shelved for the moment
August 26th, 2013 11:50 AM #20
Edited for privacy.
Last edited by saracita00; January 16th, 2014 at 05:39 PM.
Mama to C, Z, E, P, D, & G
Considerations In Progress for Agent 007
Horatio Frederic Eto :: Horatio Ethan Amadeus
Rainier Ozias Ethan :: Rainier Ozias Eto
girl names shelved for the moment
August 26th, 2013 09:20 PM #22
Last edited by saracita00; January 16th, 2014 at 05:39 PM.
Mama to C, Z, E, P, D, & G
Considerations In Progress for Agent 007
Horatio Frederic Eto :: Horatio Ethan Amadeus
Rainier Ozias Ethan :: Rainier Ozias Eto
girl names shelved for the moment
August 26th, 2013 10:45 PM #24
Okay I'm coming at this from a completely different angle than I have in the past. For me all the great names are great because of their awesome associations with characters in books or movies/tv...so here is my list of feisty fictional heroines! (Edited to match the CEPZTS ban as much as possible)
Wendy - Peter Pan, of course! Potential long forms include Gwendolyn (your Gwen name?) and Wednesday (I actually know one!)
Belle - My most favorite of the Disney princesses. Brave, loyal, selfless, curious, defiant, kind, and gentle...with a lust for books and adventure and the ability to see past appearances. What an awesome namesake! Potential long forms include Isobel, Isabella et al, Belladonna (too many Tooks?), Belphoebe, and the ultra-Southern Dulcibel just for kicks and giggles. I actually quite like "just Belle" especially paired with sister Eve!
Amelia - Amy Pond from Doctor Who. I loved the way he said her name: "Oh that's a brilliant name! Amelia Pond...like a name in a fairytale!"
Satine - probably a little TOO sexy, but I've always loved this Moulin Rouge character...her haunting lyrics, and how proud and brave she is despite being doomed from the start
Isana - from Jim Butcher's Codex Alera series. A strong, independent woman, resourceful, and fiercely protective of her loved ones. An alternative to Susannah
Phoebe - my favorite Charmed sister. Beautiful, powerful, and with this minxish pixie cuteness
Heidi - from the Johanna Spyri novel. Who didn't want to be Heidi growing up? I think she's a great balance of cute and sexy a la Heidi Klum
Bridget - a saint and mythological figure, goddess of healing, poetry, and smithcraft. Fire is sacred to her. She features in several good fantasy series.
River - too much with Evie? I have both River and Eve on my list now... Rivers Tam and Song are the ultimate badass sci-fi heroines.
Shirley - as in Anne of Green Gables. Avonlea could also work, such a beautiful place name!
Winry - awesome mechanic in Fullmetal Alchemist, sweet and charming but more than capable of holding her own in a fight, and a whiz with machinery
ANY of Tamora Pierce's heroines: Daine (Veralidaine Sarrasri) the warrior-mage and shape-shifter who could talk to animals, Alanna who disguised herself as her twin brother so she could train as a knight, Thayet the independent queen who fights for equality, Alianne spymaster for the Trickster god, etc. etc. etc.
Lyra - Belacqua (or Silvertongue) from the His Dark Materials trilogy, quite possibly my favorite series of all time. Precocious, practical, innocent, wicked, wise, vulnerable, and passionate...Lyra embodies all the intensity and complexity of what it means to be human, and yet she is utterly magical
Fern - of Charlotte's Web. Or Charlotte for that matter!
and last but not least: Cimorene - every girl's perfect heroine. Seriously. If you've not read Dealing with Dragons, you MUST. And Cimorene is a soft C, so she only bends the no-C rule, she doesn't actually break it...
And on a random note, if you like Octavia but not the oct- part, there's also Flavia, which means golden one. Easy way to Fia too!Zion Nathaniel ~ Solomon Fable ~ Balthazar Wolf ~ Malachi Sparrow nn Kai ~ Tobias Rowan ~ Caspian _____
Alice Willow ~ Ophelia Wren ~ Juliet Snow ~ Lucia Pearl ~ Eve Wisteria nn Evie ~ Cosima Rose ~ River Seraphine ~ Elowen Briar
Narnia Rose, Astoria nn Story, Illyria, Serafina, Soraya, Faerydae
Orion Melchior North, Tobias Loki, Edmund, Frost, Oberon, Kenshin, Remiel, Atreyu


text:
A DUDLEY disability group is celebrating after receiving a cash boost from a Merry Hill supermarket.
Over the last few weeks shoppers at Asda have been asked to vote for their favourite charities using green tokens given out at the till - with Dudley CIL (Centre for Inclusive Living) one of the choices.
The group, which offers free support to people living with disabilities in the borough, was founded by Dudley couple, Ken and Tracey McClymont in 2010 and the pair visited the store to claim their windfall after the coins were converted into £50 cash.
The money has enabled volunteers to organise an information day so people can find out more about the work they do.
The event will take place on Wednesday, December 5 at Brierley Hill Methodist Church, Bank Street between 12pm - 4pm and is open to people with disabilities, carers, volunteers and those who support disabled residents in the borough.
During the session a number of volunteers will be on hand to talk about available services over free tea and cake.
Tracy McClymont, Secretary for Dudley CIL said, "We are looking forward to meeting and working with our colleagues across the borough to try to make life a bit better for our fellow disabled citizens and are delighted that Asda has given us a helping hand to do this".
For more information about the event call 01384 348095.


text:
BP Comment Quick Links
|Strength of Schedule Report
April 2, 2013
Fantasy Freestyle
As Good as They Once Were?
Borrowing a bit from Toby Keith's hit a few years back:
I ain't as good as I once was
We have all seen pitchers decline as they age, losing velocity on their fastballs or crispness on their breaking pitches. Pitchers, like most assets, eventually see their talent depreciate. The pertinent question is, can some of them stem that tide or even turn it around?
From 2009 to 2012, four starting pitchers saw their strikeout percentage drop each year: Tim Lincecum, Wandy Rodriguez, Ricky Nolasco, and Jon Lester.
If we were to rank those pitchers by their 2013 ADP, Lester comes in first at 128, Lincecum next at 142, Rodriguez next at 287, and Nolasco trails the trio at 419. Nolasco is an afterthought at that draft spot, but people are rather high on Lester after his strong spring and Lincecum's name value combined with his strong post-season showing in relief has kept both of them in the top 150. If either pitcher is going to earn that value, or if Rodriguez is going to be a late-round bargain in 2013, he will need to change the direction of the trendlines on the graph above.
While past performance never guarantees future results, the good news is that pitchers before these four have been able to stem the tide and turn around declining strikeout rates, with three very recent examples.
In 2012, Johnny Cueto, Chad Billingsley, and Bronson Arroyo each turned around four-year declining strikeout rates by at least two percentage points:
Since 2000, there are 32 examples of pitchers stopping four-year slides in strikeout percentages. That group averaged a three percent improvement in the fifth year after that four-year decline, and the average age at which pitchers entered the group was 29. The late Darryl Kile is the best success story, as his strikeout percentage went from 23 percent in 1996 to 13 percent in 1999, in his last season with the Rockies. In 2000, he joined the Cardinals and saw his strikeout rate jump from 13 percent up to 20 percent.
Historically, the best success story is Mike Moore. In 1984, the 24-year-old Moore struck out 17 percent of the hitters he faced in his third season in the major leagues. That percentage fell to 15 percent in 1985, 13 percent in 1986, and down to 11 percent in 1987. In 1988, Moore turned things around, striking out 20 percent of the hitters he faced and parlaying that success into a free-agent contract with the Athletics.
Since 1970, there have been 75 instances of pitchers turning around declining strikeout percentages in the fifth year after four straight years of decline. Just eight pitchers have turned that trend around by five percentage points or more: Moore, Kile, Curt Schilling, Juan Guzman, Nolan Ryan, Josh Beckett, Andy Pettitte, and Mike Hampton. In the cases of Kile and Hampton, both pitchers spent their final two years of decline with the Rockies, and a change of scenery, which pushed them out of the thin air, helped them regain their strikeout rates in year five.
Jon Lester, Tim Lincecum, and Ricky Nolasco are certainly young enough to potentially recover some dominance, but the odds are stacked against Rodriguez, who is 34. Rodriguez, after three straight seasons of striking out at least 20 percent of the hitters he faced, saw his strikeout percentage fall to 16 percent last season. Since 1970, only 11 pitchers have turned around declining strikeout rates in or after their mid-30s: Jamie Moyer, Joe Niekro, Rick Reuschel, Woody Williams, Frank Tanana, David Wells, Jamie Moyer, Jim Kaat, Greg Maddux, David Cone, and Tom Seaver. The highest strikeout rate of any of those pitchers in that turnaround season was David Cone, who struck out 18.7 percent of the hitters he faced in 2001 at age 34, while everyone else in that sample was at 17.3 percent or lower.
Rodriguez ain't as good as he once was, and that's just the cold hard truth.
Thanks to the BP stats team for their help with pulling the data used in this article.
Jason Collette is an author of Baseball Prospectus.
8 comments have been left for this article.
BP Comment Quick Links
Miguel Tejada occasionally used As Good As I Once Was as his walk-up music at Camden Yards back in 2011. Truth.
Apr 02, 2013 06:19 AM
John Carter
What is ADP?
Apr 03, 2013 06:37 AM
Average Draft Position.
Apr 03, 2013 06:48 AM
Just curious, is there data to support altitude neutering curveballs? I imagine that's something you can look at relatively easily now with pitchFX data.
Apr 03, 2013 12:58 PM
Not a subscriber? Sign up today!


text:
May 22, 2013
Car crashes are the #1 killer of teens — a fact that Allstate couldn't live with. Rather than advertising to teens, we decided to change the law. We launched "Save 11," a movement designed to get Congress to pass a national teen safe-driving law. Our high impact campaign made the epidemic personal and reminded Congress that every day they didn't pass a law, 11 more teens would die.
Restricted Content
Access to this content item is restricted to:
- ANA Corporate Marketer Members
Please login below or create an account.
You may already be a member. Find out if your company is already an ANA member.


text:
The following holidays are recognized as university holidays:
The additional holiday is to be celebrated on a day declared by the President of the university. An employee will be entitled to pay for the aforementioned holidays provided the employee is in an uninterrupted pay status the last scheduled workday preceding the holiday and the first scheduled workday following the holiday. To meet eligibility requirements, paid time off must be applied consecutively and immediately following the last day worked. If an employee terminates employment, no pay will be received for holidays occurring after the last day worked even though the holidays fall within the period of the employee's projected terminal vacation leave (if any). On the last university workday preceding Christmas Day and New Year's Day, workdays for regular, full-time employees are normally reduced by two hours.


text:
Moderators: Timko, Fritz, Solty, Booter, Blake_T, Frank Delicious
Anode|ION|JOKERi|MD2|FD|TD|PD|LEGENDaParks wrote:If the posts on this forum are any indication, the PD is like a Teebird with sunshine coming out of its butthole so hard that it flies faster.
Mark Ellis wrote:For Rattler lovers:
The newest run of Rattlers is superb!!
For the 2012 Memorial (next week) the player's package includes Rattlers made in UV (ultra-violet) plastic with Dan Ginnelly's signature and a custom hotstamp. Along with the UV's (which turn purplish blue when exposed to sunlight) they also ran some in a bright robin's egg blue color.
Both colors are medium firm, grippy and flat topped. I played catch with both colors and they fly great and feel great.
I also got to look at (and acquire) the Titanium discs being introduced at the Memorial but I am not allowed to comment on them yet.
Frank Delicious wrote:Every groove is a unique snowflake of suck.
Frank Delicious wrote:Where can we buy a UV rattler?
Frank Delicious wrote:Where can we buy a UV rattler?
Roc Lover wrote:How about we electronically fill your pockets with money, and you in turn fill boxes with Uv Rattlers (maybe some Z..) and ship them our way ?
Users browsing this forum: No registered users and 2 guests


text:
David Brahinksy - Song for the Existential Being
Thursday, April 11, 2013
Where and When
Time: 12:30 pm
Location: Presser Music Room, MMMC001, Newtown Campus
Contact: email@example.com
Event Information
David Brahinsky - Songs for Existential Being
Music of Dylan, Cohen, Mitchell, Springstein, Brahinsky and more
FREE Event! Presented by the BC3 Music Society.
For more information contact Jeff Baumeister,firstname.lastname@example.com or 215.968.8135


text:
By Varietal
Spanish flavors come alive in these spicy, juicy, cheese coated burgers.
Catfish is a very popular fish in our area of the states. The farm-raised variety is widely available in supermarkets and has a very mild flavor.
Salmon has been a staple of Northwest cuisine throughout known history, as have blueberries, both wild and cultivated.
My husband loves bagels and salmon. And he loves a great pastrami sandwich. Using the salty pastrami instead of bacon on a salmon burger married those flavors.
The Pacific Northwest is known for its fresh, flavorful salmon and delicious berries. I have always enjoyed blueberries, and thought that they would complement the mild salmon flavor.
The texture of flounder just lends itself to making a ground burger with few extra ingredients to hold it together.


text:
Agatha Ruiz de la Prada has created a marvelous world, full of colour and creativity for our childrens' shoes . The Spanish designer creates fun models straight from their crazy imagination. They have created girl's shoes in all styles but always with an original touch of fun. They will become the favourite shoe brand of little fashion lovers.
Agatha Ruiz de la Prada shoes include colourful sandals, cool trainers and girls ankle boots. For these models, the brand uses mostly premium leather so little feet will be comfortable and also to be durable so they can be worn without worry.
On Spartoo UK you can find Agatha Ruiz de la Prada with shoes made especially for kids and also women's shoes that are very elegant. If you are looking for rain boots or sandals for the beach, you'll find something your little trendsetter will love. And if you still can't decide, have a look at the brand GBB ? Another leader in kids shoes...
Current offers: All offers are valid while stocks last.
Brands excluded from our promotions:
Spartoo promotional codes are not valid on the following brands: Mellow Yellow, Sendra Boots, Chie Mihara, Minnetonka, Samsonite
Partner products:
- Spartoo promotional codes are not valid on products marked "Partner Product"
- Delivery and returns may not be free of charge for products marked "Partner Product"
10 Year Anniversary
- The drawing is open to customers who have placed at least one order over the last 24 months
- To participate in the "Win your order" drawing, you must have placed an order between Wednesday 9/3 and Sunday 20/3.
Winners will be notified by email. The refund of the order will be issued after the return period has passed, in the form of a gift voucher, as long as no return has been made and the order is still valid. Your gift voucher can be used during a one year period directly on the "Payment" page during your next order. See regulations


text:
A 500-cow dairy in western New York had made major progress in milk production — and the owner wanted to keep it going.
Last August, he laid down the gauntlet, asking his advisors how they could add 20 more pounds to the herd average by the year 2020. If implemented, it would take the herd average from 104 pounds per day to 124 pounds.
The farm is exploring various strategies, including feed quality, genetics, employee management, reproductive management, culling practices and transition cow management, according to Tom Bailey, veterinarian with Elanco Animal Health, who spoke last spring at the Central Plains Dairy Expo in Sioux Falls, S.D.
Of the strategies, it was transition cow management that Bailey emphasized during his presentation.
"If we can get these ladies" off to a good start, he said, it will solve a lot of problems.
The first 60 days of milk is when most cows leave the herd, he said. "It's not unusual to see 25 to 30 percent of the cows that freshen leave the herd before the first 60 days in milk," he added.
Bailey cited these opportunities for improvement:
• Reduce overcrowding in the pre-fresh pens. There should be enough room that all of the animals can rest comfortably and have ready access to feed. Researchers at the University of Wisconsin recommend at least 30 inches of bunk space per animal.
• Minimize pen moves within 10 days of calving. Make the moves "socially stable," Bailey said. "In other words, move cows in groups."
• Reduce stress. By giving cows more room and minimizing pen moves, there's less stress on the cows, which is very important. Right after calving, cows are already dealing with suppressed — or even dysfunctional — immune function due to sudden biological changes, so it's imperative to reduce environmental challenges as much as possible.
• Provide cooling for pre-fresh cows. When dry cows are cooled, they produce more milk in their subsequent lactation, research has shown. In one study, researchers from the University of Florida observed an increase in the proliferation of mammary cells in cooled cows during the transition period.


text:
Big Carrier Tech for the Small Carrier
Get instant & unlimited access to the Freight Rate Search, the most intelligent and feature-rich tool set in the industry, providing for any lane selected:
Monthly subscribers to truckloadrate.com have unlimited access to the Freight Rate Search which provides the market rate along with today's fuel price for any lane in the continental U.S. and Canada. Cheapest Diesel Fuel Prices, real time Truck Loads, and State inbound/outbound rate history is also included in the monthly account. Subscribers will also have access to State Rate information and the Multi-Lane Search feature.
Signup for our News Releases
Transportation Blog


text:
At the Close: Stocks Fall as Fed Governors Bicker; Morgan Stanley Leads Financials Lower
First stocks loved the Fed's decision not to taper. Now they don't know what to make of it, as markets finished lower today.
The S&P 500 fell 0.5% to 1,701.84, while the Dow Jones Industrials dropped 0.3% to 15,401.38. The Nasdaq Composite declined 0.3% to 3,765.29.
One of the big problems has been the Federal Reserve's decision not to taper but leaving open the possibility that it will if the data cooperates. Good luck figuring out what that means. And any investor looking for guidance from Fed governors will have a tough time figuring out where the Fed stands. High Frequency Economics' highlights the rift in the Fed:
Fed Presidents Dudley and Fisher had very different messages when they spoke on Monday, with Mr. Dudley defending the decision to hold off on tapering and Mr. Fisher saying it was a mistake. In a fairly downbeat speech about the outlook, President Dudley highlighted the "tightening of financial conditions that has occurred since May" and said, "We have yet to see any meaningful pick-up in the economy's forward momentum." We thought he was a bit too negative, but time will tell.
Meanwhile, political tensions in Washington are set to rise. Nomura's Alastair Newton highlights a few:
Despite deepening tensions over fiscal policy, we still think that congress will pass a new continuing resolution before end-September to fund government through to 15 December: but the risk of a shut-down does appear to have risen.
On the debt ceiling, a major confrontation now appears inevitable in October with a re-run of the mid-2011 dramatics now looking the 'best' case scenario.
Furthermore, we see cause for concern about the impact on consumer and business sentiment of the second round of sequestrations on 1 October, which will take place in a very different context to the first round, ie:
By definition, there should be less 'fat' in the system to absorb a further USD 85bn of cuts than there was in March;
As already noted, the second round will likely take place against the back-drop of ongoing and sentiment-dampening brinkmanship over the debt ceiling...
With that as the backdrop, no wonder investors weren't feeling too bullish today.
WellCare Health Plans (WCG) spiked at the end of the day on reports that Florida had renewed some contracts but could terminate them as early as the end of this year, according to Briefing.com.
General Motor (GM) gained 0.8% to $37.13 today after Moody's upgraded its credit rating to investment grade.
Morgan Stanley (MS) fell 3.4% to $27.22, the biggest drop among S&P-500 financials, on concerns that trading revenue would be down at investment banks.
Shares of Tower Group International (TWGP) fell 5.6% to $8.63, as a filing made by its CEO showing the sale of more than 1 million shares.
AbioMed (ABMD) fell 12% to $18.88 after it updated investors on the potential impact of the Centers for Medicare and Medicaid Services transition from one type of form to another.


text:
NEW YORK ( TheStreet) -- I've said it before and I'll say it again: Valuation will always matter.But in the tech sector, a complaint about a high P/E ratio is like protesting the wetness of water. Then there are relative comparisons such as Apple's ( AAPL) incredibly low P/E of 10 versus Amazon.com's ( AMZN) 3000. Investors often air legitimate concerns such as slowing growth, but Amazon has been expensive for over a decade and has never stopped growing. I've now reached a point where I can admit that not buying the stock because of valuation concerns was a mistake. Today Amazon deserves every ounce of respect it gets.
While there's no denying Amazon is solid as any, and has arguably the best CEO in the business today, there's always been another concern: When will Amazon's bottom line matter and how long can investors afford such high premiums without meaningful profits? Coming off a lackluster third-quarter, Amazon answered this call in the fourth quarter. For the period ending in December, Amazon posted net income of $97 million, or 21 cents per share, on revenue of $21.27 billion. These results were much lower than analysts' estimates of 27 cents per share on revenue of $22.26 billion. What's more, on a year-over-year basis, net income dropped 45% -- hence the constant concerns about the bottom line.
>>Read "Putting Your Capital on ICE" on TheStreet
However, revenue climbed 22% year over year, continuing its streak of sales growth that has now averaged 32% over the past six quarters. Nonetheless, Amazon still missed the Street's revenue estimates of $22.26 billion. So despite the holiday quarter expectations, Amazon missed on both the top and bottom lines. However, following the report, shares rallied up almost 10%. The Street loved that Amazon improved in the one metric for which it is often criticized -- profitability, and in particular operating margin. That overall margins arrived better than expected affirmed the company's ability to establish better competitive leverage.


text:
Kodak Pixpro SP360 4K
Capture fully-spherical 4K video
Kodak goes ruggedly underwater with its latest pocket Internet camcorder. But does it sink or swim?
Can a camera this cheap really be any good?
With 14MP, 8x zoom and image stabilisation, the M580 has a lot of features for the money
With 12MP, 10x zoom and HD video recording, is this the ideal budget all-rounder?
With 10 megapixels and 5x zoom, is it really good value for money?
The top model of Kodak's budget camera range
Everyone wants compact zoom cameras these days, so here's a low cost one from Kodak.
Kodak's latest digital picture frame has WiFi, 512MB on-board memory, and a host of online services.


text:
Home > Bottles > Cat. No. 2009-0008
Nalgene Amber Rectangular Bottle HDPE 250 mL (Case of 72)
Normally Ships: 2-5 Business Days
Other Available Sizes
Click on Cat. No. for Ordering Information
Chemical Resistance
The 2009-0008 offers resistance depending on contents according to the following chart.
Nalgene Amber Wide-Mouth Rectangular Bottles help protect light-sensitive liquids or dry materials from exposure and take up less shelf space than traditional round bottles.
High-density polyethylene with amber polypropylene screw closure
Amber HDPE reduces UV light transmissions to protect light-sensitive liquids
Rectangular shape is great for space-saving use in the freezer to -100°C (-148°F)
Excellent chemical resistance to most acids, bases and alcohols make these excellent containers to protect your valuable samples
Linerless caps provide the ultimate in leakproof protection without the use of liner that can wrinkle, cause leaks, or contaminate your reagents
Includes: Opaque amber polypropylene screw closures
Product meets the requirements for light-resistant containers per USP latest edition.


text:
- Full metal body and sideplates keep precise gear alignment under heavy loads
- Machine-cut marine grade bronze main gear with hardened stainless steel pinion
- Versa-Drag system with HT-100 washers. By rearranging the sequence of the keyed metal washers and eared HT-100 washers the reel can be set up for fishing a wide range of drag settings without additional parts.
- Live Spindle Design with free floating spool
- Internally adjustable centrifugal braking system
- Line Capacity Rings eliminate the question of how muchline you have left when fighting a fish. The three lines on the spool flange let you know when you have 1/3, 2/3 or a full spool of line. These lines also give you a benchmark for backing your superlines with monofilament.
- 5+1 shielded stainless steel bearing system
- Instant anti-reverse bearing with silent back up ratchet
Penn FTH40 Fathom Star Drag Reel
Close Window


text:
Related Products:
Raised in an affluent Southern family, Mary Todd had a voice of her own. She was highly educated and perfectly able to hold her own in any discussion. Up to this point, most First Ladies had hidden in the background, but not Mary Todd Lincoln.
Obviously, her husband's assassination troubled her deeply. She spent the years after Abraham's death in the role of martyr-widow. She moved to Europe in 1868, but returned to Chicago in 1871. She was committed to an insane asylum in 1875, but in true Mary Todd fashion, talked her way out. She died in 1882 in Springfield, Illinois.
On the obverse or heads side of the First Spouse Gold Coin is a regal portrait of Mary Todd Lincoln. It was designed and sculpted by Phebe Hemphill. The reverse or tails side of the Gold piece shows a caring Mary giving flowers and books to wounded Union soldiers during the Civil War. It was designed by Joel Iskowitz and sculpted by Phebe Hemphill.
Not yet rated. Be the first to Write a Review
We provide all of our customers with a refund, return and / or exchange on everything we sell including all bullion and certified coins. If for any reason, you have a problem, please feel free to call us. We will always do our best to accommodate you.


text:
Race cars and high-performance exotics have long been using carbon fiber body parts to cut weight and improve performance, but now that technique has trickled down to more mainstream cars. California-based Hot Rods & Hobbies recently customized a 2009 Nissan GT-R by replacing its roof, doors, hood, front fascia, and more with new body panels fashioned from the lightweight material.
The transformation took three months of work, and began with the team removing the GT-R's windows and roof panel, then replacing the latter with a full carbon-fiber piece. The same was done for the hood, doors, front fascia, side skirts, rear wing, mirrors, and other body components. Despite the trend to show off the fiber weave pattern beneath several layers of clear coat, all carbon fiber parts were painted in the factory color, which the custom shop suggests makes it "a lighter-weight sleeper."
Of course, reducing mass isn't the only way to make a car go faster: Mines Japan also upgraded the engine with a tune said to produce 600 hp, along with a new throttle body, new exhausts, and new intercooler plumbing. The modified GT-R also sports coilover suspension, upgraded anti-roll bars, carbon-ceramic brakes, and new 18-inch black wheels. Inside, the car has Japanese-spec carbon-fiber seats, carbon fiber trim, a built-in radar detector, and an iPod connection.
The GT-R was built for a customer of Hot Rods & Hobbies. One very, very lucky customer, as far as we can tell…
Source: Hot Rods & Hobbies


text:
By Public Relations |
September 23, 2009
Bethel College will host the first Epic International Skate Fest on Saturday, Sept. 26. Sponsored by the Bethel College Longboard Association and Epic Church, skaters from at least six states will compete in several categories like Hybrid Slalom and Downhill Slide. The event starts at 9 a.m. and ends with awards at 5 p.m.
Peter Metzger, Bethel senior and coordinator of the event, says skateboarding among the student body has skyrocketed in recent years at Bethel. He hopes to bring more awareness to slalom skating through this event.
"It's a type of skating I see growing in our part of the country and I wanted to provide a place for it to happen. I also wanted this to be an opportunity for people to try out slalom and witness many types of skating," says Metzger.
This is a spectator free event where audience applause will judge some contests. Anyone can compete and those who want to can sign up for a small fee. For more information, contact Peter Metzer at firstname.lastname@example.com.
Bethel College is an accredited Christian college offering associate, bachelor's and master's degrees in more than 70 areas of study. The current enrollment of more than 2,100 includes students from 34 states and Puerto Rico, 19 countries, more than 25 denominations and 16 percent from culturally diverse backgrounds. Scholarships are available based upon a variety of factors including academic achievement, talent in the arts or athletics, ethnicity and church affiliation. In addition to its beautifully wooded 75-acre main campus in Mishawaka, Ind., Bethel also offers specific academic programs at sites in Elkhart, Ind., Fort Wayne, Ind., Dowagiac, Mich., and St. Joseph, Mich. Nursing programs are also offered in cooperation with Grace College in Winona Lake, Ind.


text:
Wednesday, May 22, 2013
ISGS Office Closed Monday, May 27, 2013
The ISGS Office will be closed on Monday, May 27, 2013 in honor of Memorial Day.
Regular hours will resume on Thursday, May 30, 2013.
© 2013, copyright Illinois State Genealogical Society
Share |
Posted by ISGS Publicity at 4:58 PM
Labels: ISGS Office
No comments:
Subscribe to: Post Comments (Atom)


text:
DUDLEY Council will complete the roll out of its new recycling and waste service next month.
During February, the remaining 49,000 borough households will receive two recycling bags, a grey wheelie bin for non-recyclable waste and a brochure detailing the new service – which will enable all households to recycle plastic bottles and cardboard from the kerbside.
Councillor Tracy Wood, Dudley's cabinet member for environment and culture, said: "I would like to thank our residents for their patience as we take these final steps to roll out our improved waste services.
"The new service enables us to collect more recycling from the kerbside while making more efficient waste collections."
Homes in phase three will receive their first collections of the new service in March and brochures being delivered to them will detail new collection dates.
For more information and a full list of phase three properties visit website www.dudley.gov.uk/recycling or call Dudley Council Plus on email@example.com or 0300 555 2345.


text:
Owl Eyes Cookies Recipe
5 1 1
These cookies are a real hoot, and they taste as good as they look. Each fall, it was a tradition for my Grandma to bake batches of Owl Cookies. The sweets were so tasty that we'd beg her to make them before the leaves had even begun turning. —Liz Clemons, Sumter, South Carolina
Featured In: 30 Favorite Halloween Cookies
VERIFIED BY Taste of Home Test Kitchen
- 3/4 cup butter, softened
- 1 cup packed brown sugar
- 1 egg
- 1 teaspoon vanilla extract
- 2-1/2 cups all-purpose flour
- 2 teaspoons baking powder
- 1/4 teaspoon salt
- 1 ounce unsweetened chocolate, melted
- 1/4 teaspoon baking soda
- Orange and yellow M&M's
- Whole cashews
- In a large bowl, cream butter and brown sugar. Beat in egg and vanilla. Combine the flour, baking powder and salt; add to creamed mixture. Remove two-thirds of the dough; roll into an 8-in. square on plastic wrap and set aside.
- Combine melted chocolate and baking soda until thoroughly blended; beat into remaining dough. Shape into an 8-in log. Place chocolate log at one end of the square and roll up; pinch seams together. Wrap in plastic wrap; refrigerate for at least 2 hours.
- Unwrap dough; cut into 1/4-in. slices. To form owl's face, place two slices side by side on a lightly greased baking sheet. Pinch dough at the top of the circles to form ears. Place M&M's in the center of each circle for eyes. Place a cashew in the center of the face for the beak.
- Bake at 350° for 9-11 minutes or until edges are lightly browned. Cool for 2 minutes before removing to a wire rack. Yield: about 1-1/2 dozen.
Originally published as Owl Cookies in Country Woman September/October 1996, p32
Reviews forOwl Eyes Cookies
My Review
Click stars to rate
Any changes to your rating or review will appear where you originally posted your review
Average Rating
Reviewed Sep. 2, 2011


text:
The title of the latest exhibit at Jack Richard Studios is 2,000 Faces, but Cuyahoga Falls artist Jack Richard said that there are actually more prints on display. Much more.
"Actually, it's more like 2,600," Richard said. "We are still setting it up."
If the concept sounds familiar, that's because, Richard said, he did this nine years ago, and it was very popular.
"We had 5,000 visitors from 86 cities, 19 states and six countries," Richard said. He added that this information came from those who had signed the studio's guest book. "Six hundred people played the games, and we gave out 4,000 prints as prizes."
This time around, all of the faces on display are from drawings, sketches and paintings Richard has done during his lengthy career -- with one exception.
"There is one photograph in the entire display," Richard said.
Once again, visitors coming to see this exhibit can play a game connected to 2,000 Faces, although the details haven't been ironed out for the second go-around yet, Richard said. But common themes could include finding the animals in the exhibit, finding the presidents, and finding the portraits of such actors like Bob Hope.
"There are a dozen pictures of Bob Hope alone," Richard said, "although some might be hard to recognize because of the makeup he was wearing."
Sumi art painter's work on exhibit
Sylvia Yin Tsui, a Sumi art painter who had a studio in Tallmadge and who has taught at the Cuyahoga Valley Art Center and at Jack Richard Studios, has examples of her work on display through the end of February. She currently lives in Arlington, Texas. Richard said she has won several awards for her work, including the National Arts Competition of Taiwan in 1964.
Gallery information
Jack Richard Studios is at 2250 Front St. in Cuyahoga Falls. For details on the exhibits or for hours, call 330-929-1575.
Email: email@example.com
Phone: 330-541-9438


text:
Every time we put out a call for help, we are blown away by the generosity of WBTV viewers.
The Charlotte Rescue Mission does Thanksgiving in style every year for hundreds of people who need a meal.
But this year, the nonprofit was in trouble. They weren't going to be able to make that tradition a reality on their own, and they reached out to WBTV for help.
Reverend Tony Marciano told us Wednesday, "We're short on turkeys. We have 125 donated. Normally by this time we have 500 donated to the rescue mission. So obviously we're in desperate need of turkey donations."
After the story aired Wednesday night, the phone at the Rescue Mission started ringing and people starting dropping in – donating money, time, and food.
By Friday afternoon, almost 100 people had stopped in at the Rescue Mission and dropped off food. Others called with money donations. McGrann Paper Corporation sent a shipment of 250 frozen turkeys.
Reverend Marciano says "Charlotte, thank you. You have an incredible heart. You came to the need when Charlotte Rescue Mission was short of turkeys".
The owner of McGrann told WBTV he heard the plea, and since he could help - he did.
Jill Norman handed over a donation Friday afternoon. She said, "I heard the plea on your news report - just wanted everybody to have a happy Thanksgiving."
Sally Honeycutt and her husband stopped by to deliver about 65 canned goods and boxes of other food items. She says her daughter works at Crown Point Family Physicians and "they took up donations today for the Rescue Mission".
Charlie Smith brought over 5 turkeys after he saw the news report. He's not surprised people responded. "I think they know it's Thanksgiving. The weather is getting cold - be a lot of people who need some good cooking on Thursday. We're just glad to be able to do it".
The Rescue Mission says a woman walked in with several hundred dollars. She told them she saw the story on WBTV and went around asking everyone she knew to donate. Two men did the same thing – going to work Thursday morning and gathering donations from coworkers.
An elementary school called and offered two turkeys – and asked if the Rescue Mission could come talk to the students about what the Rescue Mission does.
All of these donations will help make the Charlotte Rescue Mission's Thanksgiving dinner a success. This year, the Rescue Mission is doing something a little extra too – delivering baskets to people who are homebound and can't afford to buy food.
They expect to make 1,200 meals. Rico Blake, the Food Service Manager at the Rescue Mission, says he expects to cook "300 pounds of potatoes, 150-to-200 pounds of green beans, 50-to-75 pounds of ham".
The Rescue Mission now has dozens of volunteers lined up for Monday to help make and deliver those Thanksgiving baskets, too.
Reverend Marciano says "this Thanksgiving is going to be an incredibly memorable day for hundreds of people whose Thanksgiving Holiday would not have been had it not been for you. On their behalf, thank you".
Of course, anyone who still wants to help is welcome. The Rescue Mission says it also delivers meals to other shelters, so there is no such thing as too many donations - nothing will be wasted.
You can drop off turkeys or other donations at the Charlotte Rescue Mission's uptown location – 907 West First Street – diagonal from the Carolina Panthers practice field.
You can also call Jill at 704-334-4635 x240.
Copyright 2012 WBTV. All rights reserved.
"My instinct and training tells me that a smoke means there's going to be a fire, and a car has gasoline in it," Hinkle said.More >>
"My instinct and training tells me that a smoke means there's going to be a fire, and a car has gasoline in it," Hinkle said.More >>
1812 Fairfield Ave.
Shreveport, LA 71101
(318) 222-1212
(318) 222-1212EEO Report Closed Captioning
All content © Copyright 2000 - 2017 Raycom Media. All Rights Reserved. For more information on this site, please read our Privacy Policy, and Terms of Service, and Ad Choices.


text:
Master's Degrees Conferred at 2011 Graduate Commencement
Muskingum University granted master's degrees at its 2011
graduate commencement exercises, held on May 5. The address was
delivered by 1964 alumnus Demetrios Lignos who is known as "the father
of digital linear tape," for his breakthrough invention of the medium
while he was with Digital Equipment Corporation.
In recognition of his lifetime of achievement, the university bestowed upon Mr. Lignos an honorary doctor of science degree.
Lignos has changed the world through his pioneering technological
innovation and has enhanced the lives of others through his dedication
to service. He is known internationally as the "father of Digital
Linear Tape" (DLT) for his 1984 breakthrough invention for the Digital
Equipment Corporation. DLT changed the nature of computer data storage
and retrieval, opening new opportunities for technological applications
and economic growth. It quickly became the industry standard for
backups of essential files and remains the standard for transferring
original content to DVD format for commercial replication and
distribution of motion pictures, music, and other media content.
During his distinguished forty-year career, Mr. Lignos held
principal roles in engineering design, technology, and product
development at industry-leaders Digital Equipment Corporation, Quantum
Corporation, Maxtor Corporation, and InPhase Technologies. He was
responsible for the development of more than a dozen major computer
peripheral and data storage products, guiding them through creation,
testing, manufacturing, marketing, sales, and adoption by customers
Mr. Lignos has received numerous electronics design and
engineering honors, including the coveted "R&D 100 Award"
recognizing the most technologically significant new products. He is a
prolific author of technical articles and conference presentations.
He earned his Muskingum Bachelor of Science degree in Physics
with a Mathematics minor, and received a Muskingum University
Distinguished Service Award in 2009. He also holds a Master of Science
degree in Engineering Science from the University of Toledo and a Master
of Business Administration degree from the University of New Hampshire.
An accomplished boater, he holds the highest level of boating
education certification from the United States Power Squadron and
teaches marine electronic courses to fellow boaters. He is a visitor
guide at the Mote Marine Laboratory and Aquarium, and is active in many
church, civic, and cultural organizations.
He and his wife, Raynette Lyons Lignos '64, reside in Lakewood Ranch, Florida. They are the parents of Theodore (Ted) Lignos.
Maps & Directions
Academic Affairs
Undergraduate Admission
Financial Aid
Graduate & Continuing Studies
Business Office
Academic Catalogs


text:
In America, red may mean, "Come to a complete and safe stop," but to Mark Course, an electrical engineer in Deer Park, Victoria, Australia, the color that ignites 83,000 receptor cones in the human eye means just one thing: go, go, go.
Course recently imported a '64 Riverside Red Corvette coupe with matching Red interior to the former British colony, and he's been lighting up Australian roads with his acquisition ever since.
"I've always loved Corvettes, and I sold my award-winning '32 Ford hot-rod coupe to buy this Sting Ray," Course says. "I was going to buy a first-gen, but a salesman in the U.S. told me to set my sights on a midyear. Though I didn't buy one from him, I took his advice."
The Aussie found his '64 four-on-the-floor Corvette on an Internet for-sale site, and then asked the seller-a New Jersey collector-car dealer-to send him digital photos of it, along with details. He learned that the classic C2's previous owner had installed an '81 350 (which he had stroked to 383 cubic inches, thanks to an aftermarket 3.75-inch crank and 4.030-inch pistons); aluminum heads (set at a 10:1 compression-ratio); a Holley 850-cfm carburetor; an MSD 6AL ignition kit; headers; and 3-inch Corvette-style sidepipes. Its cam specs were undisclosed.
The car had rare factory options, too: power windows (only 3,706 Vettes were built with them in 1964) and air-conditioning (an even scarcer option that kept 1,988 new- Corvette owners cool in their cars that year).
Course says the retina-burning red Sting Ray, "...looked like a show winner with its shiny paint, polished chrome and other brightwork, aggressive stance, and Centerline race wheels [15x5.5 and 15x7, to be precise, wrapped in Nexan 205/70R15 and 215/70R15 rubber]."
The '64 Corvette was a winner in new-car showrooms, too. A total of 22,229 of them were manufactured for the model year, continuing a streak of yearly sales increases that started in 1956 and continued through 1966. A 327ci small-block was the only engine offered, and depending on which variant was ordered, its performance was rated at 250, 300, or 365 horses in carbureted form. Specifying the L84 Rochester mechanical fuel-injection system nudged the mouse motor's output to 375 hp.
Course says it was only a day from the moment he saw the Corvette's photos before he consummated the transcontinental sales contract. It then took several months for the Sting Ray to make its way by slow boat to Australia. "They were the scariest months," he says.
Eventually, he received a call from the customs broker where his Corvette had berthed, but his wait was not over yet. As he recalls, "I had to drive eight hours to the port of call and verbally wrestle with the broker over paperwork that was not right. Finally, the Australian authorities allowed me to see my Corvette in person for the first time, and then take delivery of it.
"I wanted to drive it so badly," he continues. "So I trailered it home, fired up the engine, and tested the brakes. The wrong pedal was going to the metal! I had no choice but to park the car and begin my first Corvette mod: modernizing the vintage stopping system with a dual-reservoir master cylinder, 13-inch big-brake rotors, and C5 calipers." He also upgraded the chassis' road-hugging potential with a Vette Brakes and Products sway-bar kit (11?8-inch front, 3?4-inch rear) and Bilstein Sport shocks at all four corners.
The performance- addicted Australian didn't stop there. Wanting to know how much power his Corvette churned out, he took the car to a nearby dyno shop, where it was strapped to the rollers and revved to its limit. He was rewarded with impressive numbers for his combo-418 hp at the rear wheels. Afterwards, he bought his car a gift-a new Centerforce dual-friction clutch.
More recently, Course turned his attention to his Corvette's exterior, careful not to stray from the marque's iconic, head-turning aesthetics. He installed a '67-style big-block hood, sourced from Eckler's, and painted a contrasting longitudinal white stripe onto the body.
Likewise, he left the cabin mostly original looking, including the vinyl-covered seats, door panels, carpet, gauges, four-speed console, and shifter. He did add new chrome knobs, a glovebox, a Moon shifter-handle ball, and an AM/FM/CD stereo that bolted into the factory radio mounting location and bears the Corvette logo.
His future mods include leather seat covers (red, of course), and squeezing even more performance out of his stroked small-block.
Course's enjoyment of his Corvette isn't too much different than that of many domestic Corvette owners-vintage, late-model, and brand-new alike. "I attend club events, race at local racetracks, and if I've had a bad day at work, I jump in the car and head out for a cruise," he says. "There's something about the color red on a Corvette that just makes me want to go." Vette
There's something about the color red on a Corvette that just makes me want to go -Mark Course
Spec Sheet
|'64 coupe
|Mark Course; Deer Park, Victoria, Australia
|'81 Corvette cast-iron SBC
|383 ci
|Compression Ratio
|Unknown aluminum aftermarket
|Rocker Arms
|Intake Manifold
|Unknown aluminum aftermarket
|Holley 850-cfm four-barrel
|Fuel Pump
|Exhaust System
|Headers with 3-in side pipes
|Stock four-speed manual
|VB&P sway bars, Bilstein Sport shocks
|13-in rotors, C5 calipers
|Centerforce; 15x5.5 (front), 15x7 (rear)
|Nexan; 205/70-15 (front), 215/70-15 (rear)
|3,125 lbs (factory shipping weight)
|Current Mileage
|Approx. 7,650


text:
Used Morris for sale in Kelty
We currently have 0 used Morris cars available in Kelty. With the widest range of private and trade Morris cars available in Kelty, you have access to the biggest choice and the best prices.
Feel free to browse our selected vehicles, further refine your search, and find your perfect car.
Latest second hand Morris cars for sale in Kelty
Sorry, it looks like we have no used Morris cars available in Kelty
However we currently have: 1 Used Morris car available in Scotland on Auto Trader
Selection of the latest second hand Morris cars for sale in Scotland
|Showing 1 result
Morris Mini Moke 0.8 Convertible 0.9 5dr
1965 (C reg) Hatchback
Green, Coming Soon, £27,000